<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880851</url>
  </required_header>
  <id_info>
    <org_study_id>Mbase HyPro 2.0</org_study_id>
    <nct_id>NCT03880851</nct_id>
  </id_info>
  <brief_title>MR-based Hypofractionated Adaptive IGRT of Prostate Cancer (M-base HyPro 2.0)</brief_title>
  <acronym>Mbase_HyPro</acronym>
  <official_title>Single-arm Phase (II) Study on MR-based Hypofractionated Adaptive Image-guided Radiation Therapy for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-centre single-armed, non-randomized interventional phase II-study of hypofractionated
      image-guided radiotherapy &quot;IGRT&quot; with weekly magnetic resonance imagings &quot;MRI&quot; for
      personalized adaptation of the treatment plan depending on individual MR-anatomy of
      prostate/organ at risks &quot;OAR&quot; during course of IGRT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IGRT-schedule: 20 fractions to a total dose of 60 Gy

      Personalized adaption of treatment plan dependning on volume-/ and constraint-thresholds and
      evaluation of biomarkers (multiparametric MRI, blood, tissue, stool, urine).

      Treatment at MR-Linac allowed
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase II, Intervention: Plan adaption in case of significant changes of organ at risk or target volumes measured in weekly MRIs</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with gastrointestinal &quot;GI&quot; and genitourinary &quot;GU&quot; toxicity of &gt;/= G2</measure>
    <time_frame>2 years</time_frame>
    <description>Hypothesis: reduction of GI/GU-toxicity (CTC-criteria 4.0, RTOG) from 20% to 10% at 2 years, power 80%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants completing at least 2 of 4 MRI-examinations during course of IGRT</measure>
    <time_frame>6 months</time_frame>
    <description>Feasibility and tolerability of completing at least 2 of 4 MRIs during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants achieving local control</measure>
    <time_frame>2, 5, 10 years</time_frame>
    <description>In case of PSA progress: No evidence of local recurrence detected by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants achieving regional control</measure>
    <time_frame>2, 5, 10 years</time_frame>
    <description>In case of PSA progress: No evidence of regional recurrence detected by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants achieving Distant-metastasis-free survival &quot;DMFS&quot;</measure>
    <time_frame>2, 5, 10 years</time_frame>
    <description>No evidence of distant metastases diagnosed by cross-sectional imaging including bone scan, MRI, CT and PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with biochemical no evidence of disease &quot;bNED&quot;</measure>
    <time_frame>2, 5, 10 years</time_frame>
    <description>biochemical no evidence of disease according to Phoenix definition: nadir + 2ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time without secondary treatment &quot;TWIST&quot;</measure>
    <time_frame>2, 5, 10 years</time_frame>
    <description>Time without secondary treatment calculated from start of IGRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTC-Proctitis</measure>
    <time_frame>2, 5, 10 years</time_frame>
    <description>CTC 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTC-Incontinence</measure>
    <time_frame>2, 5, 10 years</time_frame>
    <description>CTC 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival &quot;PFS&quot;</measure>
    <time_frame>2, 5, 10 years</time_frame>
    <description>progression-free survival is defined as any progression (biochemical or other recurrences) or death or initiation of secondary treatment, calculation from start of IGRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival &quot;OS&quot;</measure>
    <time_frame>2, 5, 10 years</time_frame>
    <description>Overall survival is calculated from start of IGRT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Hypofractionated image-guided radiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hypofractionated image-guided radiotherapy &quot;IGRT&quot; to a total dose of 60 Gy (20 fractions) is performed.
Weekly MRI are used to estimate volume/deformation changes of OAR and target volume.
Intervention: In case of a significant change of target volume or OARs (threshold based) the radiation treatment plan is adapted on individual MR-anatomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Plan adaptation of Radiation Treatment in case of anatomical changes</intervention_name>
    <description>Image guided radiotherapy is given to 60Gy in 20 fractions. Intervention: Radiation treatment plan adaption in case of volume changes of target volume or not meeting OAR constraints due to volume changes.</description>
    <arm_group_label>Hypofractionated image-guided radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  biopsy-proven prostate cancer with indication for RT

          -  cT1b-cT3a cN0 cM0

          -  ECOG Performance score 0-2

          -  IPSS≤12 (before planning computed tomography i.e. reached after neoadjuvant androgen
             deprivation therapy or tamsulosin)

          -  age&gt;18 years

          -  Informed consent

        Exclusion Criteria:

          -  not fulfilled inclusion criteria

          -  contraindication against curative RT

          -  age&lt;18 years

          -  previous pelvic radiotherapy or planned pelvic radiotherapy

          -  comorbidities interfering with image-guided radiotherapy

          -  contraindications against multiparametric MRI (like hio prosthesis, pacer, allergy
             against contrast media)

          -  prior transurethral resection, highly focussed ultrasound or other pre-treatment of
             prostate
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Silke Theden</last_name>
    <phone>+49707183420</phone>
    <email>silke.theden@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arndt-Christian Müller</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Müller Arndt-Christian</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt-Christian Müller</last_name>
      <phone>070712986143</phone>
      <email>arndt-christian.mueller@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Arndt-Christian Mueller</investigator_full_name>
    <investigator_title>Deputy Head of the Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>hypofractionation</keyword>
  <keyword>MR-based IGRT</keyword>
  <keyword>Mbase HyPro</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

